Dr. Reddy's Laboratories Ltd. (RDY)
Stock Price Chart
Key Info
| Market Cap | 10.10B |
| Revenue (ttm) | 2.32B |
| Net Income (ttm) | 258.59M |
| Shares Out | 166.23M |
| EPS (ttm) | 1.40 |
| PE Ratio | 43.41 |
| Forward PE | 31.35 |
| Dividend | $0.33 |
| Dividend Yield | 0.54% |
Stock Quote
| Trading Day | Aug 7, 2020 |
| Last Price | $60.78 |
| Previous Close | $61.18 |
| Change ($) | -0.40 |
| Change (%) | -0.65% |
| Day's Open | 61.01 |
| Day's Range | 60.20 - 61.12 |
| Day's Volume | 64,889 |
| 52-Week Range | 33.33 - 61.95 |
More Stats
| Market Cap | 10.10B |
| Enterprise Value | 10.05B |
| Earnings Date (est) | Oct 29, 2020 |
| Ex-Dividend Date | Jul 10, 2020 |
| Shares Outstanding | 166.23M |
| Float | 120.37M |
| EPS (basic) | n/a |
| EPS (diluted) | 1.40 |
| FCF / Share | 2.57 |
| Dividend | $0.33 |
| Dividend Yield | 0.54% |
| Earnings Yield | 2.30% |
| FCF Yield | 4.23% |
| Payout Ratio | 17.10% |
| Shares Short | 1.49M |
| Short Ratio | 7.75 |
| Short % of Float | n/a |
| Beta | 0.10 |
| PE Ratio | 43.41 |
| Forward PE | 31.35 |
| P/FCF Ratio | 23.63 |
| PS Ratio | 4.36 |
| PB Ratio | 4.74 |
| Revenue | 2.32B |
| Operating Income | 212.11M |
| Net Income | 258.59M |
| Free Cash Flow | 427.47M |
| Net Cash | 48.25M |
| Net Cash / Share | 0.29 |
| Gross Margin | 53.84% |
| Operating Margin | 9.16% |
| Profit Margin | 11.20% |
| FCF Margin | 18.46% |
| ROA | 8.64% |
| ROE | 12.12% |
| ROIC | 12.60% |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 174,600 | 153,851 | 142,028 | 140,809 | 154,708 | 148,189 | 132,170 | 116,266 | 96,737 | 74,693 |
| Revenue Growth | 13.49% | 8.32% | 0.87% | -8.98% | 4.4% | 12.12% | 13.68% | 20.19% | 29.51% | - |
| Gross Profit | 94,009 | 83,430 | 76,304 | 78,356 | 92,281 | 85,403 | 75,801 | 60,579 | 53,305 | 40,263 |
| Operating Income | 15,993 | 20,888 | 11,917 | 13,498 | 29,619 | 26,286 | 26,032 | 21,112 | 18,252 | 12,629 |
| Net Income | 19,498 | 18,795 | 9,806 | 12,039 | 20,013 | 22,179 | 21,515 | 16,777 | 14,262 | 11,040 |
| Shares Outstanding | 166 | 166 | 166 | 167 | 171 | 170 | 170 | 170 | 169 | 169 |
| Earnings Per Share | 117.40 | 113.09 | 59.00 | 72.09 | 116.98 | 129.75 | 126.04 | 98.44 | 83.81 | 64.95 |
| EPS Growth | 3.81% | 91.68% | -18.16% | -38.37% | -9.84% | 2.94% | 28.04% | 17.46% | 29.04% | - |
| Dividend Per Share | 0.27 | 0.29 | 0.29 | 0.30 | 0.29 | 0.59 | 0.26 | 0.23 | 0.90 | 0.24 |
| Dividend Growth | -8.56% | 0.69% | -2.36% | 1.71% | -50.17% | 121.97% | 15.28% | -74.64% | 276.25% | - |
| Operating Cash Flow | 36,946 | 33,545 | 20,790 | 27,283 | 48,261 | 30,431 | 26,550 | 18,854 | 20,698 | 8,009 |
| Capital Expenditures | -4,715 | -5,690 | -9,152 | -12,234 | -11,933 | -9,167 | -9,996 | -6,606 | -6,816 | -8,718 |
| Free Cash Flow | 32,231 | 27,855 | 11,638 | 15,049 | 36,328 | 21,264 | 16,554 | 12,248 | 13,882 | -709 |
| Cash & Equivalents | 25,740 | 24,757 | 20,968 | 18,136 | 39,955 | 39,653 | 33,534 | 22,099 | 18,152 | 5,762 |
| Total Debt | 22,102 | 38,381 | 50,714 | 49,185 | 33,513 | 43,126 | 44,742 | 36,760 | 32,210 | 23,572 |
| Net Cash / Debt | 3,638 | -13,624 | -29,746 | -31,049 | 6,442 | -3,473 | -11,208 | -14,661 | -14,058 | -17,810 |
| Assets | 232,241 | 225,427 | 225,604 | 219,821 | 207,650 | 194,762 | 170,223 | 142,369 | 119,477 | 95,005 |
| Liabilities | 77,253 | 85,230 | 99,144 | 95,777 | 79,314 | 83,460 | 79,422 | 69,564 | 62,033 | 49,015 |
| Book Value | 154,988 | 140,197 | 126,460 | 124,044 | 128,336 | 111,302 | 90,801 | 72,785 | 57,444 | 45,990 |
Company Profile
Company Details
| Full Name | Dr. Reddy's Laboratories Ltd. |
| Country | India |
| Employees | 21,650 |
| CEO | Erez Israeli |
Stock Information
| Ticker Symbol | RDY |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NYSE: RDY |
Description
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. The company also engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2020, it had four late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology. The company was founded in 1984 and is headquartered in Hyderabad, India.